Combining capabilities to grow: Navitas acquires KAI Research

By Maggie Lynch

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags Clinical trials Clinical research Clinical trial management Fda Nih Cdc Africa North america

Navitas has acquired KAI Research to expand its trial site footprint in North America and Africa as well as bolster its ability to manage clinical trials in a number of research areas.

Based in the US, KAI will provide Navitas will its existing relationships with clinical sites as well and its network of service providers in the US and in Africa. According to a spokesperson for Navitas, KAI will continue to work with the US government through clinical research contracts in areas of emergent and epidemic infectious diseases with a priority on the African continent supported by partners and sites throughout Africa.

The spokesperson added that through this agreement Navitas’ ability to interact with KAI’s network will put the company in a “unique standpoint in serving federal agenices like the US Food and Drug Administration (FDA), National Institute of Health (NIH), Center for Disease Control (CDC), and Department of defense.”

Per the acquisition, Navitas will also obtain KAI’s e-clinical solutions and patient registries which will enable the company to expand its Phase II and III capabilities in North America and add to its offerings in Europe.

The spokesperson added, “The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets.  Combining these operational and TA capabilities with our proprietary AI driven OneClincial platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us

Products

View more

Webinars